Effects of neuropeptide Y on regulation of blood flow rate in canine myocardium. 1990

J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
Department of Medicine B, Rigshospitalet, University of Copenhagen, Denmark.

The effect of neuropeptide Y (NPY) on tension development was examined in isolated canine coronary arteries, and the effects on local myocardial blood flow rate were studied in open-chest anesthetized dogs by the local 133Xe washout technique. By immunohistochemistry, numerous NPY-like immunoreactive nerve fibers were identified in the adventitia of canine coronary arteries. NPY (10(-9)-10(-6) M) supplied to isolated epicardial segments of the left anterior descending coronary artery induced a modest vasoconstriction, with a maximum tension of 0.95 mN, that was only 6.9% of the response to K+. In contrast, intracoronary NPY (0.01-10 micrograms) induced a considerable degree of vasoconstriction; the reduction of blood flow rate was dose related, with a maximum reduction to 52% of control values. The effect of intracoronary NPY (1 microgram) on maximally relaxed arterioles elicited by 30 s of ischemia was studied in separate experiments during reactive hyperemia. NPY induced a decrease in maximum blood flow during reactive hyperemia (166.6 vs. 214.6% of preocclusive blood flow rate, mean values; P = 0.05), an increase in the cumulative excess blood flow (61.0 vs. 35.3 ml/100 g; P = 0.02), and an increase in the duration of reactive hyperemia compared with control values (66 vs. 41 s; P = 0.02). Thus we conclude that in the heart NPY is a potent vasoconstrictor that seems to act preferentially on smaller intramyocardial arterioles. Furthermore, NPY inhibits vascular relaxation of myocardial resistance vessels after ischemia, suggesting that this peptide may participate in the regulation of myocardial blood flow not only during physiological conditions but also after ischemia.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D009478 Neuropeptide Y A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones. Neuropeptide Y-Like Immunoreactive Peptide,Neuropeptide Tyrosine,Neuropeptide Y Like Immunoreactive Peptide,Tyrosine, Neuropeptide
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006940 Hyperemia The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous). Active Hyperemia,Arterial Hyperemia,Passive Hyperemia,Reactive Hyperemia,Venous Congestion,Venous Engorgement,Congestion, Venous,Engorgement, Venous,Hyperemia, Active,Hyperemia, Arterial,Hyperemia, Passive,Hyperemia, Reactive,Hyperemias,Hyperemias, Reactive,Reactive Hyperemias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
July 2001, Acta oto-laryngologica,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
February 1988, European journal of pharmacology,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
September 1991, British journal of pharmacology,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
March 1992, Brain research,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
June 1985, Lancet (London, England),
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
December 1989, Journal of cardiovascular pharmacology,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
May 1993, The American journal of physiology,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
January 1990, Peptides,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
November 1980, Circulation research,
J H Svendsen, and S P Sheikh, and J Jørgensen, and J D Mikkelsen, and W P Paaske, and P Sejrsen, and S Haunsø
September 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Copied contents to your clipboard!